[go: up one dir, main page]

MX2019009419A - Compuesto que tiene actividad agonista del receptor de somatostatina y uso farmaceutico del mismo. - Google Patents

Compuesto que tiene actividad agonista del receptor de somatostatina y uso farmaceutico del mismo.

Info

Publication number
MX2019009419A
MX2019009419A MX2019009419A MX2019009419A MX2019009419A MX 2019009419 A MX2019009419 A MX 2019009419A MX 2019009419 A MX2019009419 A MX 2019009419A MX 2019009419 A MX2019009419 A MX 2019009419A MX 2019009419 A MX2019009419 A MX 2019009419A
Authority
MX
Mexico
Prior art keywords
compound
somatostatin receptor
agonistic activity
present
activity
Prior art date
Application number
MX2019009419A
Other languages
English (en)
Inventor
Yoshida Atsushi
Ishida Akiharu
Miyata Hidenori
SHONO Tomoyuki
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of MX2019009419A publication Critical patent/MX2019009419A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona un agonista del receptor de somatostatina subtipo 2. Un compuesto descrito en la presente invención representado por la fórmula general (I): (en donde todos los símbolos tienen los mismos significados que las definiciones descritas en la descripción) o una sal del mismo es un compuesto de bajo peso molecular que tiene una fuerte actividad agonista para el receptor de somatostatina del subtipo 2. El compuesto de acuerdo con la presente invención se puede administrar por vía oral, y por lo tanto, el presente compuesto se puede administrar fácilmente y contribuir a la reducción del dolor del paciente con un tratamiento terapéutico. Además el compuesto de acuerdo con la presente invención tiene una actividad inhibidora de hERG suficientemente débil y/o un efecto de fosfolipidosis en relación con la actividad agonista de SSTR2, y por lo tanto puede suprimir o aliviar los efectos secundarios que resultan de la actividad y/o efecto.
MX2019009419A 2017-02-08 2018-02-07 Compuesto que tiene actividad agonista del receptor de somatostatina y uso farmaceutico del mismo. MX2019009419A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017021363 2017-02-08
PCT/JP2018/004111 WO2018147300A1 (ja) 2017-02-08 2018-02-07 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途

Publications (1)

Publication Number Publication Date
MX2019009419A true MX2019009419A (es) 2019-10-02

Family

ID=63108324

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009419A MX2019009419A (es) 2017-02-08 2018-02-07 Compuesto que tiene actividad agonista del receptor de somatostatina y uso farmaceutico del mismo.

Country Status (15)

Country Link
US (1) US20200000816A1 (es)
EP (1) EP3581569A4 (es)
JP (1) JPWO2018147300A1 (es)
KR (1) KR20190114986A (es)
CN (1) CN110300749A (es)
AU (1) AU2018219644A1 (es)
BR (1) BR112019016433A2 (es)
CA (1) CA3053091A1 (es)
IL (1) IL268444A (es)
MX (1) MX2019009419A (es)
PH (1) PH12019501802A1 (es)
RU (1) RU2019124888A (es)
SG (1) SG11201907240XA (es)
TW (1) TW201835081A (es)
WO (1) WO2018147300A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3056131A1 (en) * 2017-03-16 2018-09-20 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
EP3752498B1 (en) 2018-02-12 2023-06-28 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
TW202016101A (zh) * 2018-06-15 2020-05-01 日商小野藥品工業股份有限公司 哌啶醇衍生物的新穎鹽及新穎結晶形
ES3022912T3 (en) * 2018-09-18 2025-05-29 Crinetics Pharmaceuticals Inc Somatostatin modulators and uses thereof
CN109115913B (zh) * 2018-10-03 2021-08-06 济南迪安医学检验中心有限公司 一种基于常规苯基色谱柱分离盐酸雷莫司琼和其s型对映异构体的hplc方法
CN109115914B (zh) * 2018-10-03 2021-06-04 四川中科微纳科技有限公司 一种分离盐酸雷莫司琼和其s型对映异构体的高效液相色谱方法
JP7365094B2 (ja) * 2019-04-22 2023-10-19 株式会社Ｓｃｒｅｅｎホールディングス 薬効評価方法、コンピュータプログラムおよび記録媒体
TWI841768B (zh) 2019-08-14 2024-05-11 美商克林提克斯醫藥股份有限公司 非肽生長抑制素(somatostatin)5型受體激動劑及其用途
MX2023009603A (es) 2021-02-17 2023-08-24 Crinetics Pharmaceuticals Inc Formas cristalinas de un modulador de somatostatina.
IL320483A (en) * 2022-10-28 2025-06-01 Basecamp Bio Inc Somatostatin receptor 2 agonists and uses thereof
WO2024129614A1 (en) * 2022-12-13 2024-06-20 Crinetics Pharmaceuticals, Inc. Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0862562B1 (en) 1995-09-13 2001-07-04 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
AU1285499A (en) 1997-10-30 1999-05-24 Merck & Co., Inc. Somatostatin agonists
BR9910371A (pt) 1998-05-11 2001-01-09 Takera Chemical Ind Ltd Composto, composição farmacêutica, agente para controlar os receptores relacionados com a retinóide, processos de prevenção e terapia da diabetes mellitus, de prevenção e terapia da hiperlipemia, para acentuar uma sensibilidade à insulina, para melhorar uma resistência à insulina, de prevenção e terapia da tolerância à glicose prejudicada, de prevenção e terapia de uma doença inflamatória, de prevenção de uma esclerose arterial, e, uso do composto
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
EP1227090A4 (en) 1999-10-07 2002-11-20 Tadeka Chemical Ind Ltd AMINE DERIVATIVES
JP3723071B2 (ja) 1999-11-10 2005-12-07 武田薬品工業株式会社 含窒素５員複素環化合物
WO2001082925A1 (en) 2000-04-28 2001-11-08 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonists
EP1283199A4 (en) 2000-05-16 2003-12-17 Takeda Chemical Industries Ltd MELANINE CONCENTRATING HORMONE ANTAGONISTS
US6785126B2 (en) 2001-05-07 2004-08-31 Ttools, Llc Protective case and keyboard system for a handheld computer
US20050245571A1 (en) 2001-10-19 2005-11-03 Hidenori Abe Amine derivative
AU2002363655A1 (en) 2001-11-14 2003-05-26 Novartis Ag Non-peptide somatostatin receptor ligands
TWI283670B (en) 2001-11-28 2007-07-11 Sod Conseils Rech Applic 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as a medicament
CA2506735A1 (en) 2002-11-19 2004-06-03 Hidenori Abe Indole derivatives as somatostatin agonists or antagonists
JPWO2005090332A1 (ja) * 2004-03-23 2008-01-31 萬有製薬株式会社 置換キナゾリン又はピリドピリミジン誘導体
US7803786B2 (en) 2004-06-17 2010-09-28 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions and related methods of use
US20090258853A1 (en) 2006-03-13 2009-10-15 Brian Eastman Somatostatin Agonists
JP2009155283A (ja) 2007-12-27 2009-07-16 Sumitomo Chemical Co Ltd オキサゾリジン化合物、オキサゾリドン化合物およびその中間体の製造方法
JP6299591B2 (ja) 2012-07-03 2018-03-28 小野薬品工業株式会社 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
BR112016007078A2 (pt) 2013-09-30 2017-12-12 Ono Pharmaceutical Co composto tendo atividade agonística do receptor de somatostatina e uso farmacêutico do mesmo
US9957267B2 (en) 2015-07-01 2018-05-01 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
WO2017003724A1 (en) 2015-07-01 2017-01-05 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof

Also Published As

Publication number Publication date
CA3053091A1 (en) 2018-08-16
BR112019016433A2 (pt) 2020-04-07
AU2018219644A1 (en) 2019-08-29
KR20190114986A (ko) 2019-10-10
RU2019124888A (ru) 2021-03-10
TW201835081A (zh) 2018-10-01
IL268444A (en) 2019-09-26
WO2018147300A1 (ja) 2018-08-16
PH12019501802A1 (en) 2020-03-02
EP3581569A1 (en) 2019-12-18
EP3581569A4 (en) 2020-02-19
US20200000816A1 (en) 2020-01-02
SG11201907240XA (en) 2019-09-27
CN110300749A (zh) 2019-10-01
JPWO2018147300A1 (ja) 2019-11-21

Similar Documents

Publication Publication Date Title
PH12019501802A1 (en) Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof
MX368781B (es) Compuesto inhibidor de las actividades de las cinasas btk y/o jak3.
MX2022007915A (es) Compuestos de benzopirazol y analogos de estos.
SG11201806930PA (en) Novel condensed pyrimidine compound or salt thereof
PH12020550680A1 (en) Dosage regimen of vidofludimus for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases
EP4553071A3 (en) Methods for improving mitophagy in subjects
NZ732507A (en) Improved compositions for treating muscular dystrophy
ZA202306172B (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
MY197558A (en) Methods of treating depression using orexin-2 receptor antagonists
ME02841B (me) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
MX390084B (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
NZ754764A (en) Pyrimidine tricyclic enone derivatives for inhibition of rorγ and other uses
PH12016502353A1 (en) Pharmaceutical composition
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
MY163235A (en) Pharmaceutical preparation containing pyridylaminoacetic acid compound
MX381440B (es) Composicion farmaceutica para tratar colitis ulcerativa.
TW201613577A (en) Pharmaceutical combinations
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
MX389282B (es) Composiciones y métodos para tratar sinucleinopatías.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX379373B (es) Derivado de sulfonamida heterocíclico y medicina que contiene el mismo.
EA202190398A1 (ru) Конденсированное кольцевое производное, применяемое в качестве ингибитора fgfr4